Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tramadol HCl ER, tramadol ER
Tramadol · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Tramadol HCl ER | DRUG | - |
| tramadol ER | DRUG | - |
Inclusion Criteria: * Patients with American College of Rheumatology (ACR) Functional Class I-III OA of the knee or hip * Patients with involvement of at least one knee or hip joint that warrants treatment with COX-2 inhibitors, NSAIDS, acetaminophen, or opioid analgesics for at least 75 of the 90 ...
Top 4 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Retatrutide, LY3016859, LY3556050, LY3526318, LY3857210 |
| Fortress Biotech, Inc. | FBIO | 1 | PHASE3 | Tramadol |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | MK-6916 |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
Tramadol is used for the treatment of chronic pain. It is being developed by Bausch Health Companies Inc. under the ticker BHC. The clinical program has focused on chronic pain conditions, including osteoarthritis of the knee and hip as well as chronic low back pain.
Tramadol acts as an agonist at OPRM1, the mu-opioid receptor. By binding to and activating this receptor, it interferes with pain signaling. This mechanism places Tramadol in the agonist class of small molecule pain therapies.
Tramadol is being developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company has sponsored the clinical trial program evaluating extended-release formulations of the drug for chronic pain.
Tramadol is in Phase 3 clinical development for chronic pain. It is an investigational therapy and has not been approved by the FDA for this use. The Phase 3 program includes completed trials, with no active trials currently listed.
Tramadol has been studied in four completed Phase 3 trials: NCT00348010 in knee osteoarthritis, NCT00347724 in chronic low back pain, NCT00347685 as a one-year open-label safety study, and NCT00325858 comparing multiple dose strengths in knee and hip osteoarthritis. Total enrollment across these trials was 2,495 participants.
Yes, Tramadol HCl ER and tramadol ER are alternative names for the extended-release formulation of Tramadol. These names refer to the same active drug, tramadol hydrochloride, in an extended-release dosage form developed for chronic pain.